Disclaimer:

The Competition DG makes the information provided by the notifying parties in section 1.2 of Form CO available to the public in order to increase transparency. This information has been prepared by the notifying parties under their sole responsibility, and its content in no way prejudges the view the Commission may take of the planned operation. Nor can the Commission be held responsible for any incorrect or misleading information contained therein.

SECTION 1.2

Description of the concentration

1.1.1.1 Lundbeckfond Invest A/S (“LFI”) and KIRKBI Invest A/S (“KIRKBI”) will indirectly acquire joint control in Falck A/S (“Falck”).

1.1.1.2 LFI is controlled by Lundbeckfonden, a commercial foundation established in 1954. Its main objective is to maintain and expand the activities of the Lundbeck Group, and to provide funding for scientific research of the highest quality. The commercial activities of the Lundbeck Group are carried out through the wholly-owned subsidiary LFI - which holds a substantial interest in the share capital of the two pharmaceutical companies H. Lundbeck A/S (which develops drugs for treatment of diseases of the central nervous system) and ALK-Abelló A/S (which develops allergy vaccination products).

1.1.1.3 KIRKBI is part of the KIRKBI Group headed by KIRKBI A/S. KIRKBI A/S is the holding and investment company of the Kirk Kristiansen family. KIRKBI A/S is through its subsidiaries involved in a number of businesses, of which the 75% shareholding in LEGO A/S and the 36.3% shareholding in Merlin Entertainments Group S.a.r.l are the largest.

1.1.1.4 The target, Falck, is an international assistance and emergency company directed at preventing accidents and disease; providing assistance in situations of emergency, accidents or need and helping people move on with their life after illness or accidents.

1.1.1.5 The economic and strategic rationale for the Proposed Transaction is purely investment and funding.